• Home
  • »
  • Highlights

Featured Stories

  • Alexion Inaugurates New EMEA Headquarters in Zurich

    On November 19, 2015, Alexion proudly inaugurated the new regional headquarters for Europe, Middle East and Africa in Zurich. We dedicate our office and our work to patients and their families living with rare and devastating diseases. We are committed to delivering life-transforming therapies to patients in need every day. The opening ceremony was attended by representatives from the business communities as well as members of the local life science cluster and political representatives. Read the press release.

  • European Commission Approves Strensiq® and Kanuma®

    The European Commission has approved Kanuma® (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-D), and Strensiq® (asfotase alfa) for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. Both Kanuma and Strensiq are the first therapies approved in the EU for the treatment of these life-threatening, ultra-rare metabolic disorders. Read the Kanuma press release and the Strensiq press release. For more information, please refer to the full Summary of Product Characteristics (SmPC) for Kanuma and for Strensiq.